000449052 001__ 449052
000449052 005__ 20250716152033.0
000449052 0247_ $$2doi$$a10.3390/pharmaceutics12020106
000449052 0247_ $$2datacite_doi$$a10.3204/PUBDB-2020-03577
000449052 0247_ $$2pmid$$apmid:32013056
000449052 0247_ $$2WOS$$aWOS:000519268500076
000449052 0247_ $$2altmetric$$aaltmetric:118850893
000449052 0247_ $$2openalex$$aopenalex:W3003533868
000449052 037__ $$aPUBDB-2020-03577
000449052 041__ $$aEnglish
000449052 082__ $$a610
000449052 1001_ $$0P:(DE-HGF)0$$aJanisova, Larisa$$b0$$eCorresponding author
000449052 245__ $$aMolecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
000449052 260__ $$aBasel$$bMDPI$$c2020
000449052 3367_ $$2DRIVER$$aarticle
000449052 3367_ $$2DataCite$$aOutput Types/Journal article
000449052 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601038546_17073
000449052 3367_ $$2BibTeX$$aARTICLE
000449052 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000449052 3367_ $$00$$2EndNote$$aJournal Article
000449052 520__ $$aThe binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery. 
000449052 536__ $$0G:(DE-HGF)POF3-6G3$$a6G3 - PETRA III (POF3-622)$$cPOF3-622$$fPOF III$$x0
000449052 588__ $$aDataset connected to CrossRef
000449052 693__ $$0EXP:(DE-H253)P-P12-20150101$$1EXP:(DE-H253)PETRAIII-20150101$$6EXP:(DE-H253)P-P12-20150101$$aPETRA III$$fPETRA Beamline P12$$x0
000449052 7001_ $$00000-0001-8598-5491$$aGruzinov, Andrey$$b1
000449052 7001_ $$00000-0003-1646-9981$$aZaborova, Olga V.$$b2
000449052 7001_ $$00000-0002-4950-1071$$aVelychkivska, Nadiia$$b3
000449052 7001_ $$00000-0003-1190-8535$$aVaněk, Ondřej$$b4
000449052 7001_ $$00000-0002-7135-9796$$aChytil, Petr$$b5
000449052 7001_ $$00000-0001-5908-5182$$aEtrych, Tomáš$$b6
000449052 7001_ $$0P:(DE-HGF)0$$aJanoušková, Olga$$b7
000449052 7001_ $$aZhang, Xiaohan$$b8
000449052 7001_ $$0P:(DE-H253)PIP1009408$$aBlanchet, Clement$$b9
000449052 7001_ $$00000-0002-7098-3458$$aPapadakis, Christine M.$$b10
000449052 7001_ $$0P:(DE-H253)PIP1001422$$aSvergun, Dmitri I.$$b11
000449052 7001_ $$00000-0002-4253-5076$$aFilippov, Sergey K.$$b12
000449052 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics12020106$$gVol. 12, no. 2, p. 106 -$$n2$$p1-9$$tPharmaceutics$$v12$$x1999-4923$$y2020
000449052 8564_ $$uhttps://www.mdpi.com/1999-4923/12/2/106
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.pdf$$yOpenAccess
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.gif?subformat=icon$$xicon$$yOpenAccess
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000449052 8564_ $$uhttps://bib-pubdb1.desy.de/record/449052/files/Molecular%20Mechanisms%20of%20the%20Interactions%20of%20N-%282-Hydroxypropyl%29methacrylamide%20Copolymers%20Designed%20for%20Cancer%20Therapy%20with%20Blood%20Plasma%20Proteins.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000449052 909CO $$ooai:bib-pubdb1.desy.de:449052$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000449052 9101_ $$0I:(DE-588b)235011-7$$6P:(DE-H253)PIP1009408$$aEuropean Molecular Biology Laboratory$$b9$$kEMBL
000449052 9101_ $$0I:(DE-HGF)0$$6P:(DE-H253)PIP1009408$$aExternal Institute$$b9$$kExtern
000449052 9101_ $$0I:(DE-588b)235011-7$$6P:(DE-H253)PIP1001422$$aEuropean Molecular Biology Laboratory$$b11$$kEMBL
000449052 9131_ $$0G:(DE-HGF)POF3-622$$1G:(DE-HGF)POF3-620$$2G:(DE-HGF)POF3-600$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF3-6G3$$aDE-HGF$$bForschungsbereich Materie$$lVon Materie zu Materialien und Leben$$vFacility topic: Research on Matter with Brilliant Light Sources$$x0
000449052 9141_ $$y2020
000449052 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000449052 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2018$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000449052 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-10
000449052 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-10
000449052 9201_ $$0I:(DE-H253)EMBL-User-20120814$$kEMBL-User$$lEMBL-User$$x0
000449052 9201_ $$0I:(DE-H253)EMBL-20120731$$kEMBL$$lEMBL$$x1
000449052 980__ $$ajournal
000449052 980__ $$aVDB
000449052 980__ $$aUNRESTRICTED
000449052 980__ $$aI:(DE-H253)EMBL-User-20120814
000449052 980__ $$aI:(DE-H253)EMBL-20120731
000449052 9801_ $$aFullTexts